



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

12/4/01

TECH CENTER 1600/2900

DEC 03 2001

RECEIVED

In application of: ALDERSON et al.

Application Serial No.: 09/499,468

Group Art Unit: 1633

Filed: February 7, 2000

Examiner: Sorbello, E.

Title: Vascular Endothelial Growth Factor-2

Atty. Docket No.: PF112U1

INFORMATION DISCLOSURE
STATEMENT PURSUANT TO 37 § CFR 1.56

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys for Applicants hereby direct the Examiner's attention to references AA-FT listed on the attached Form PTO/SB/08A. A copy of each of reference(s) AA-FT is enclosed.

Attorneys for Applicants further wish to bring to the attention of the Examiner:

- (a) Statutory Declaration of Peter Adrian Walton Rogers executed on November 12, 2001, and exhibits PAWR-1 through PAWR-14;
- (b) Statutory Declaration of Peter Adrian Walton Rogers executed on February 16, 2000, and exhibit 1;
- (c) Statutory Declaration of Kari Alitalo executed on February 15, 2000, and exhibits 1-3;
- (d) Statutory Declaration of Francis John Ballard and exhibit 1; and
- (e) Statutory Declaration of Kari Alitalo executed on September 24, 2001, and exhibits 1-2.

The exhibits accompanying the above-listed declarations are references which were brought to the attention of the Applicants in connection with an opposition to an Australian

application, that essentially corresponds to the U.S. priority application in this case. Copies of each of the above-listed Declarations and accompanying exhibits thereto, are enclosed.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR §§ 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.


Identification of the listed reference(s) is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Applicants respectfully request that the Examiner review the listed reference(s) and that the reference(s) be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), since this information disclosure statement is being filed before the mailing date of a first Office Action on the merits, no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Human Genome Sciences, Inc., deposit account no. 08-3425.

Respectfully submitted,

Dated: 11/29/01


Michele M. Wales (Reg. No. 43,975)
Attorney for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, Maryland 20850
Telephone: (301) 610-5772

Enclosure
MMW/AKR/lcc